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The data described here is related to the research article titled
(Gabl et al., 2016) [1]. Pepducins with peptide sequence derived
from one of the intracellular domains of a given G-protein coupled
receptor (GPCR) can either activate or inhibit cell functions. Here
we include data on human neutrophil function induced by pep-
ducins derived from β2AR (ICL3-8) and CXCR4 (ATI-2341),
respectively. ICL3-8 exerts neither direct activating effect on the
NADPH-oxidase as measured by superoxide release nor inhibitory
effect on FPR signaling. ATI-2341 dose-dependently triggers neu-
trophil activation and these cells were subsequently desensitized
in their response to FPR2 speciﬁc agonists F2Pal10 and WKYMVM.
Moreover, the ATI-2341 response is inhibited by PBP10 and the
peptidomimetic Pam-(Lys-betaNSpe)6-NH2 (both are FPR2 speciﬁc
inhibitors), but not to the FPR1 speciﬁc inhibitor cyclosporine H.
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcation Tableubject area Biology
ore speciﬁc sub-
ject areaG-protein coupled receptor signalingvier Inc. This is an open access article under the CC BY license
/j.bbamcr.2016.03.014
obile: þ46 070 8701899.
(H. Forsman).
T
H
D
E
E
D
Fig
pep
the
the
am
sen
tim
(10
ﬁgu
add
pro
acti
A. Holdfeldt et al. / Data in Brief 8 (2016) 411–414412ype of data. 1. No direct activating o
ducin ICL3-8. A) Human
addition of the Gs modu
FPR2 speciﬁc agonist F
pliﬁed chemiluminescen
tative curves out of at lea
e points for addition of s
mM) at 37 °C for 5 min be
re, representative curve
ition of F2Pal10. Inset: th
duction (induced by the
vity induced in cells incFigures
ow was data
acquiredIsoluminol ampliﬁed chemiluminescence; luminometerata format Processed
xperimental
factorsIsolated human neutrophils were activated by pepducin or receptor speciﬁc
agonists and the responses induced were determinedxperimental
featuresThe effects of receptor speciﬁc inhibitors and desensitization proﬁles were
determinedata source
locationGothenburg, Swedenata accessibility Data are within this articleD
Value of the data
 Receptor speciﬁc neutrophil responses can be determined by the sensitive assay to measure
superoxide production.
 The precise receptor involved can be identiﬁed by the desensitization proﬁle and by the use of
deﬁned receptor speciﬁc antagonists.
 The data provide insights into the highly variable effects of pepducins which includes receptor
hijacking.1. Data
Data describes human neutrophil activation, measured by isoluminol-enhanced chemilumines-
cence systems, with two pepducins derived from β2AR (ICL3-8) and CXCR4 (ATI-2341), respectively.
Direct neutrophil activation by ICL3-8 and its modulatory effect on FPR signaling are shown (Fig. 1). In
addition, data on dose-dependent neutrophil activation induced by ATI-2341 and the effects on this
response of FPR speciﬁc agonists as well as antagonists are provided (Fig. 2).r inhibitory effect on the FPR-mediated NADPH-oxidase response is induced by the Gs modulating
neutrophils (105 cells) were pre-incubated with latrunculin A (25 ng/ml) at 37 °C for 5 min before
lating pepducin ICL3-8 (1 mM, solid line), the FPR1 speciﬁc agonist fMLF (100 nM, dotted line) and
2Pal10 (1 mM, dashed line). Superoxide production was continuously measured by isoluminol-
ce. The inset shows the response induced by the ICL3-8 pepducin with higher resolution. Repre-
st ﬁve independent experiments using individual blood donors are shown. The arrows indicate the
timuli. B) Human neutrophils (105 cells) were pre-treated with either ICL3-8 (1 mM) or histamine
fore activation with F2Pal10 (1 mM; main ﬁgure and inset) or fMLF (100 nM; only inset). In the main
s out of at least ﬁve independent experiments are shown. The arrow marks the time point for
e inhibitory effect of ICL3-8 (black bars) and histamine (white bars) on FPR-mediated superoxide
FPR1 agonist fMLF or the FPR2 agonist F2Pal10) expressed as percent inhibition compared to the
ubated without any inhibitor (mean7SD, n¼4). N.I. equals no inhibition.
Fig. 2. The CXCR4 pepducin ATI-2341 triggers a direct activation of the neutrophil NADPH-oxidase through FPR2. A) ATI-2341
dose-dependently triggers neutrophil superoxide production, as measured by isoluminol-ampliﬁed chemiluminescence. Data
are presented as normalized peak response with the ﬁtted curves. The EC50 value and the 95% conﬁdence interval were cal-
culated from 8 independent experiments. Inset: A representative ATI-2341 (1 mM) induced neutrophil response is shown.
Abscissa, Time of study; Ordinate, Superoxide production (arbitrary units). B) Desensitized neutrophils incubated for 5 min at
37 °C without (solid lines) or with 1 mM ATI-2341 (dash lines) were activated with the FPR2 speciﬁc agonist F2Pal10 (1 mM; main
ﬁgure) or the FPR1 speciﬁc agonist fMLF (100 nM, inset). Arrows indicate the time point for agonist addition. C) Neutrophils
were pre-incubated for 5 min at 37 °C without any additive, with either of the two FPR2 speciﬁc inhibitors PBP10 (1 mM) or
HF965A (1 mM), or with the FPR1 speciﬁc inhibitor cyclosporin H (CysH, 1 mM). The neutrophils were then activated with ATI-
2341 (1 mM) and superoxide production was recorded by isoluminol-ampliﬁed chemiluminescence. The results are expressed
as percent inhibition compared to the activity induced in cells incubated without any inhibitor (mean7SD, n¼7). N.I. equals
no inhibition.
A. Holdfeldt et al. / Data in Brief 8 (2016) 411–414 4132. Experimental design, material and methods
2.1. Neutrophil isolation
Human neutrophils were isolated from buffy coates as described [2], and diluted to 1106/ml in
Krebs-Ringer phosphate buffer (KRG) containing glucose (10 mM), Mg2þ(1.5 mM), and Ca2þ(1 mM).
The cells were kept on ice until use. Ethics approval was not needed since the buffy coats were
provided anonymously and could not be traced back to a speciﬁc individual. This is in line with
Swedish legislation section code 4§ 3p SFS 2003:460 (Lag om etikprövning av forskning som avser
människor).2.2. The NADPH-oxidase assay and receptor desensitization protocol
The release of superoxide anions from activated neutrophils was measured using isoluminol/HPR
ampliﬁed chemiluminescence systems [3]. Vials with reaction mixtures of 900 ml containing iso-
luminol (20 mM), HRP (4U), neutrophils (1105/ml) with or without antagonist were incubated for
A. Holdfeldt et al. / Data in Brief 8 (2016) 411–4144145 min at 37 °C. For receptor desensitization, cells were either activated or pre-incubated with receptor
speciﬁc agonist for 5 min before stimulation. Stimuli (100 ml) were added and the light emission was
recorded continuously.
2.3. GPCR pepducins and FPR speciﬁc ligands
The FPR2 pepducin F2Pal10 (Pal-KIHKKGMIKS, amino acid sequence from a part of third intra-
cellular loop of FPR2), the β2AR pepducin ICL3-8 (Pal-LQKIDKSEGRFHV, amino acid sequence from a
part of the third intracellular loop of β2AR) [4], and the CXCR4 pepducin ATI-2341 (Pal-
MGYQKKLRSMTDKYRL, amino acid sequence from the ﬁrst intracellular loop of CXCR4) [5] were from
Caslo Laboratory (Lyngby, Denmark). All the other FPR1 and FPR2 speciﬁc ligands used have been
described earlier [6].Acknowledgments
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